A Study Assessing Perfusion Outcomes With PINPOINT® Near Infrared Fluorescence Imaging in Low Anterior Resection (PILLAR III)
A Randomized, Controlled, Parallel, Multicenter Study Assessing Perfusion Outcomes With PINPOINT® Near Infrared Fluorescence Imaging in Low Anterior Resection
Sponsor: Novadaq Technologies ULC, now a part of Stryker
Terminated
Slow recruitment
A NA clinical study on Rectal Cancer and Rectosigmoid Cancer, this trial is terminated or withdrawn. The trial is conducted by Novadaq Technologies ULC, now a part of Stryker and has accumulated 13 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Terminated NA
-
Sep 2024 — Sep 2025 [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2023 — Jul 2024 [monthly]
Terminated NA
-
Dec 2022 — Jan 2023 [monthly]
Terminated NA
▶ Show 8 earlier versions
-
Dec 2021 — Dec 2022 [monthly]
Terminated NA
-
Jan 2021 — Dec 2021 [monthly]
Terminated NA
-
Jul 2020 — Jan 2021 [monthly]
Terminated NA
-
Mar 2019 — Jul 2020 [monthly]
Terminated NA
-
Jun 2018 — Mar 2019 [monthly]
Terminated NA
-
Jul 2017 — Jun 2018 [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Feb 2017 — Jul 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Jan 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novadaq Technologies ULC, now a part of Stryker
For direct contact, visit the study record on ClinicalTrials.gov .